clinical trial · NCT02568267
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Breast CancerCholangiocarcinomaColorectal CancerHead and Neck NeoplasmsLymphoma, Large-Cell, AnaplasticMelanomaNeuroendocrine TumorsNon-Small Cell Lung CancerEntrectinib
brief summary
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
started
Nov 19, 2015
primary completion
Jun 30, 2027
completion
Jun 30, 2027
last updated
Aug 25, 2026
official title
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol